News
BASEL, Switzerland I June 12, 2025 I Novartis announced positive results from APPULSE-PNH, a Phase IIIB study evaluating the efficacy and safety of ...
Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025
ZURICH-SCHLIEREN, Switzerland and CONCORD, MA, USA I June 11, 2025 I Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company ...
COPENHAGEN, Denmark I June 12, 2025 I SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for ...
BARCELONA, Spain I June 11, 2025 I SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations ...
SAN DIEGO, CA, USA I June 11, 2025 I Capstan Therapeutics, Inc. (“Capstan”), a clinical-stage biotechnology company dedicated to advancing in vivo ...
INCHEON, Korea I June 12, 2025 I Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) today presented the long-term safety data of EPYSQLI™ (eculizumab; SB12), a ...
Capsida is initiating the Phase 1/2 study for CAP-003, with the first patient expected to be dosed in the third quarter of this year ...
In the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label HALOS study, ION582 provided consistent and encouraging clinical improvement on all functional domains including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback